ACROSTUDY (Pfizer International Somavert® Database) includes data on patients with acromegaly receiving Somavert® (pegvisomant for injection). ACROSTUDY uses a standardized procedure for collection of clinical data. It is an important evidence based medicine tool that contributes to a wider understanding of Somavert® treatment.
ACROSTUDY has been collecting data since 2004 and now contains data on more than 2,000 patients from 15 countries.
Pfizer International Somavert® Database
-includes data on patients with acromegaly receiving Somavert®.
If you have any questions regarding ACROSTUDY, please contact Ferah Aydin, ACROSTUDY Manager.
Here, you will find information from ACROSTUDY Highlights Sessions held at different congresses and symposia.
Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY
Ann Endocrinol (Paris) 2015 Nov 17